News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 672 results
December 2008
-
Media ReleaseVideo: Gleevec Receives US Approval as First Treatment To Reduce Risk of Cancer Returning in Patients with Gastrointestinal Stromal Tumors
-
Media ReleaseRAD001 Shows Potential to Reverse Resistance to Herceptin®* in Metastatic Breast Cancer Patients, Leading to Phase III Trial- RAD001 combined with Herceptin and chemotherapy in two separate Phase I trials halted tumor growth in 77% and 62% of patients, respectively- Novartis to start Phase III clinical trial program to…
-
Media ReleaseRAD001 Shows Potential to Reverse Resistance to Herceptin®* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
November 2008
-
Media ReleaseVideo: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!'- Partnership aims to provide convenient access to vaccination - helping keep kids and teachers in school and parents at work- "Let's Fight Flu Together!" initiative supports CDC's new vaccination…
-
Media ReleaseVideo: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!'
October 2008
-
Media ReleaseEarly Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease-- Exploratory study shows clinical improvement in patients with pulmonary arterial hypertension (PAH) -- Current treatment options have limited benefit for this debilitating, rapidly progressive and…
-
Media ReleaseEarly Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
September 2008
-
Media ReleaseRAD001 Combined with Sandostatin LAR® Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors- 82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR Depot- 77% of patients with pancreatic NET…
-
Media ReleaseRAD001 Combined with Sandostatin LAR® Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
-
Media ReleaseRAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer-- Regulatory applications to be submitted worldwide for RAD001 first submissions filed in the Hidden List US, EU and Switzerland -- Data showing that RAD001 more than doubles time without tumor…
-
Media ReleaseRAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
Pagination
- ‹ Previous page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- › Next page